Clinical Trial

Zanzalintinib in Unresectable and Progressive MPGGs

Name: Zanzalintinib in Unresectable and Progressive MPGGs — clinical trial record (NCT07714551)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.

Trial Details

NCT Number	NCT07714551
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Exelixis
Conditions	Pheochromocytoma, Paraganglioma
Enrollment	14 participants
Start Date	2027-01-09
Primary Completion	2031-01-01 (estimated)
Study Completion	2032-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-20